Fragile X Syndrome

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval

Medical CBD Company Zynerba Rallies On Q4 Report, CEO Says 2020 Outlook 'Promising'

Zynerba Advances Cannabidiol Treatment With New Patent Win

Medical CBD Company Zynerba Rallies On Q4 Report, CEO Says 2020 Outlook 'Promising'

Zynerba Advances Cannabidiol Treatment With New Patent Win

Analyst Upgrades Zynerba, Encouraged By Prospects For Fragile X Phase 2 Study

How Important Is Zynerba's ZYN002 For Children Suffering From Fragile X Syndrome?

Fragile X Syndrome Recent News

For Rare Neural Diseases, Is Ovid Therapeutics The Right Team At The Right Time?

Catalysts Growing Like Weeds For Zynerba Next Quarter

It's High Time For Zynerba Positives: Investors Await 3 Key Mid-Stage Trial Reads On Cannabidiol ZYN002

Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail

Zynerba Could See 3 Clinical Study Catalysts In 2017's First Half

A Higher Probability For Success Is Not Baked Into Zynerba's Valuation